Sage Therapeutics, Inc.

Wyeth

Richardson-merrell Inc.

Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Hoechst Marion Roussel

Siena Biotech S.p.a.

Sage Therpeutics, Inc.

Aventis Pharmaceuticals Inc.

Marion Merrell Dow Canada Inc.

Gestion De La Sante Marion Merrell Dow Canada Inc.-marion Merrell Dow Canada Health Management Inc.

Boyd L. Harrison

Bruce M. Baron

Boyd Lynn Harrison

Francesco Gerald Salituro

Albert Jean Robichaud

Gabriel Martinez Botella

Richard Thomas Beresis

Andrew Mark Griffin

Joseph E Dolfini

Bruce M Baron

Daniel La

Anthony Frank Kreft

Scott Christian Mayer

George Diamantidis

Molly Hoke

Derek Cecil Cole

Minsheng Zhang

Philip L Nyce

Benny C Askew

David M Stemerick

Maria Jesus Blanco-Pillado

Ravindra B Upasani

Lynn Resnick

Rocco John Galante

Tingzhong Wang

Wayne Everett Childers

Robert Jason Herr

George Ku

Niall S Doherty

Robert Borbo Kargbo

Jean-Cosme Dodart

Michael Sotirios Malamas

Michael G Kelly

Ian A McDonald

Ping Zhou

Gan Zhang

Thomas Joseph Caggiano

Donna Mary Huryn

Dennis Michael Kubrak

Paul Jeffrey Dollings

John Gregory Reid

Iwan Suwandi Gunawan

Christopher R Dalton

Robert A Farr

Alexander Greenfield

Arlene J Dietrich

Koi Morris

Simon Nicolas Haydar

Yanfang Li

James Joseph Erdei

Charles William Mann

Lisa Marie Havran

P Sivaramakrishnan Ramamoorthy

Byron Abel Bravo

Lee Erwin Schechter

Diane Barbara Hauze

Zhongqi Shen

Russell J Baumann

James Jacob Bicksler

Alexander Michael Porte

Maurizio Varrone

Arianna Nencini

Chae-Koo Dan Chong

Raymond S Gross

Robert Farr

Scott B Meikrantz

Iolanda Micco

Riccardo Zanaletti

Laura Maccari

Hendrick Bothmann

Carmela Pratelli

Pawel Wojciech Nowak

Vasilios Marathias

Chiara Ghiron

Bruce Michael Baron

Ian A Mcdonald

Gabriel Martinezbotella

Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R, R, n, R, R, R, and Rare as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

C7 substituted oxysterols and methods of use thereof

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, R, R, R, R, R, R, R, R, and Rare as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein, R, R, R, Rand A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

Compositions and methods for treating CNS disorders

Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R, R, R, R, R, R, and Rare as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Oxysterols and methods of use thereof

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L, L, L, X, X, Y, R, R, R, n, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

Neuroactive steroids, compositions, and uses thereof

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, Y, R, R, R, R, R, R, R, R, R, R, and Rare as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R, R, R, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein, A, R, R, R, R, R, R, R, and Rare as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R, R, R, R, R, R, R, R, R, R, R, R, andare as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.

C7, C12, and C16 substituted neuroactive steroids and their methods of use

Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R, R, R, R, R, R, R, R, Randare as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.

19-nor neuroactive steroids and methods of use thereof

3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.

Neuroactive steroids and methods of use thereof

Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R, and Rare as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Compounds are provided according to Formula (III): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R, R, R, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Growing community of inventors

Princeton Junction, NJ, United States of America

Boyd Lynn Harrison